Short Interest in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Expands By 8.0%

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was the target of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 5,530,000 shares, an increase of 8.0% from the December 15th total of 5,120,000 shares. Based on an average daily volume of 831,700 shares, the days-to-cover ratio is presently 6.6 days. Approximately 10.0% of the shares of the stock are short sold.

Analyst Ratings Changes

Several brokerages have issued reports on AGIO. Leerink Partners downgraded Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $60.00 to $56.00 in a research report on Friday, September 27th. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Raymond James reaffirmed an “outperform” rating and issued a $51.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Leerink Partnrs cut shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. Finally, Scotiabank raised their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, December 9th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $56.33.

Insider Transactions at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the transaction, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 4.93% of the stock is owned by insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of institutional investors have recently made changes to their positions in AGIO. Caxton Associates LP grew its position in shares of Agios Pharmaceuticals by 0.7% during the 2nd quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company’s stock worth $1,615,000 after buying an additional 264 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 363 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Agios Pharmaceuticals by 6.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company’s stock worth $539,000 after purchasing an additional 688 shares during the period. Acadian Asset Management LLC bought a new position in shares of Agios Pharmaceuticals during the second quarter worth $37,000. Finally, Federated Hermes Inc. grew its holdings in shares of Agios Pharmaceuticals by 9.0% in the 2nd quarter. Federated Hermes Inc. now owns 13,394 shares of the biopharmaceutical company’s stock valued at $578,000 after buying an additional 1,108 shares during the period.

Agios Pharmaceuticals Stock Performance

Shares of AGIO stock opened at $32.42 on Tuesday. The firm’s 50 day moving average price is $44.16 and its two-hundred day moving average price is $45.03. Agios Pharmaceuticals has a 52-week low of $20.96 and a 52-week high of $62.58. The stock has a market cap of $1.85 billion, a PE ratio of 2.85 and a beta of 0.87.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.